Opinion|Videos|March 7, 2025
Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment
Experts discuss the role of reflex testing in ensuring accurate and timely treatment selection, the challenges it may present, and how it can be integrated with next-generation sequencing (NGS) to provide a comprehensive molecular profile while minimizing delays.
Advertisement
Episodes in this series
Video content above is prompted by the following:
• What is the role of reflex testing, and how does it ensure accurate and timely treatment selection?
• What challenges might arise from the use of reflex testing?
• How can reflex testing be integrated with NGS to provide a comprehensive molecular profile while minimizing delays?
Advertisement
Related to this article
Phase 1a data in 16 patients with recurrent glioblastoma established a recommended dose for expansion of LP-184 for a planned phase 1b/2a combination trial.
The FDA set a June 25, 2027, PDUFA date for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy.
The FDA approved pimicotinib for TGCT based on phase 3 MANEUVER data showing durable responses and improved pain, stiffness, and function.
Real-world data showed a 68% 12-month high-grade recurrence-free survival rate with hyperthermic mitomycin C in patients with BCG-unresponsive NMIBC.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
The FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid tumors who may be eligible for pembrolizumab.
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
3
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
4
Top 3 Poster Takeaways in Liver Cancer Care From The Liver Meeting 2026
5